Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
Karyopharm Therapeutics (Nasdaq: KPTI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026.
Rhea-AI Summary
Karyopharm Therapeutics (Nasdaq: KPTI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. The company’s management will host a conference call and live audio webcast at 8:00 a.m. ET the same day to review results and provide company updates.
Investors can join the call by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes before the start and requesting the Karyopharm Therapeutics call. A live webcast with slides will be available under “Events & Presentations” in the investor section of the company’s website, with an archived replay accessible about two hours after the event.
Positive
- None.
Negative
- None.
Details
Market move: KPTI -7.55% in the Aug 10 session. 2Q26 earnings report
On Aug 10, the day this news came out, KPTI closed 7.55% below the previous close. Argus tracked a peak move of +5.0% during that session. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner recorded 16 alerts for this stock that day.
Data tracked by StockTitan Argus for the Aug 10 session.
Key Figures
- Reporting period
- Q2 2026
- Financial results to be reported
- Results date
- August 13, 2026
- Scheduled reporting date
- Conference call time
- 8:00 a.m. ET
- August 13, 2026 conference call and webcast
Previous Earnings date Reports
-
Scheduled first-quarter 2026 results and an 8:00 a.m. ET conference call
-
Scheduled fourth-quarter and full-year 2025 results with an investor webcast
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET --
To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026-302845213.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.